

Biosimilars

F O R U M

Contact:

Aimee Steel Lubin
202.828.1895
aimee.lubin@hklaw.com

Media:

Lynn Blenkhorn
508.851.0930
biosimilars@fkhealth.com

Biosimilars Forum Statement Regarding the Retirement of John Jenkins, Longtime Director of the FDA's Office of New Drugs

Washington, DC, December 7, 2016 – The Biosimilars Forum – the nonprofit organization solely dedicated to expanding patient access to biosimilars in the United States today issued the following statement regarding the retirement of John Jenkins, longtime Director of the FDA's Office of New Drugs.

“The Biosimilars Forum wishes to congratulate John Jenkins on his retirement from the FDA. The Forum has been pleased with Mr. Jenkins’ leadership and willingness to work with the Forum on BSUFA II and establish the biosimilars program in the United States. This is a vital program to American consumers; in an effort to continue the progress, it is the Forum’s hope that the FDA moves quickly to name a successor. We wish John all the best for the future and thank him for his public service.”

About the Biosimilars Forum

The Biosimilars Forum is a nonprofit organization whose mission is to advance biosimilars in the United States with the intent of expanding access and availability of biological medicines, and improving health care. The founding members of the Biosimilars Forum represent the majority of companies with the most significant U.S. biosimilars development portfolios.

To learn more about biosimilars, the Forum, and how to get involved, visit BiosimilarsForum.org or go to [@USbiosimilars](https://twitter.com/USbiosimilars) to follow related conversations and join the dialogue.